Showing: 1 - 2 of 2 RESULTS

WellCare of Nebraska Will Rebrand as Healthy Blue in January, Reflecting a New Alliance With Blue Cross and Blue Shield of Nebraska

Members’ health plan benefits and services will remain the same.

Community Care Health Plan of Nebraska, Inc. (dba WellCare of Nebraska), which is an Anthem Inc. company and leading managed care provider of health benefits for Nebraska’s Heritage Health Medicaid program, along with Blue Cross and Blue Shield of Nebraska (BCBSNE), the largest health insurer in Nebraska, have received approval to enter into an alliance to collaboratively serve Medicaid beneficiaries across the state.

In support of this venture, the Nebraska health plan known as WellCare will be rebranded as Healthy Blue to reflect the strength of its new alliance with BCBSNE, as well as to extend brand stability and recognition of the Blue Cross and Blue Shield name to its Heritage Health Medicaid members. This name change will take effect on Jan. 1, 2021.

“Through this joint venture, we are bringing together proficiency in building best-in-class Medicaid programs with expertise that comes from being the state’s oldest and largest health insurer,” said Tim Meyers, health plan president. “We both have a shared interest in addressing the unique needs of Nebraska’s Medicaid beneficiaries and alleviating Nebraska’s most pressing health issues. Through our shared mission, we are confident that we will succeed in building healthier, stronger communities across our state.”

Approximately 83,000 health plan members, who participate in the state’s Heritage Health Medicaid program, will be notified through the mail to inform them of the change to their health plan’s name. Members should expect to receive new Healthy Blue member ID cards with the Blue Cross and Blue Shield logo before January 1, 2021. Existing WellCare of Nebraska member ID cards should be used through the end of 2020.

Members will also continue to receive the same healthcare benefits and have access to their established primary care providers, specialists and care centers. This rebrand will not have any impact on BCBSNE health plan members or providers.

“We have been here for millions of Nebraskans throughout their health journeys and believe that ensuring care access and equity is fundamental to the health and well-being of our communities,” said Steve Grandfield, president and chief executive officer of BCBSNE. “In collaboration with a fellow industry leader, we look forward to equipping more people across our state with the power and peace of mind a Blue card provides.”

When the name change takes effect on Jan. 1, 2021, the current member website will be redirected to a new Healthy Blue website, and members should begin using the new customer service phone numbers printed on their Healthy Blue ID cards. Current members who do not receive their new Healthy Blue ID cards by Jan. 1, or those who have questions may contact member services at 855-599-3811 (TTY 877-247-6272), Monday – Friday, 8:00 a.m. – 5:00 p.m. CST, or visit myhealthybluene.com.

About Community Health Plan of Nebraska, Inc.

Community Care Health Plan of Nebraska, Inc. (“CCHPN”), an Anthem Inc. company that is formally known as WellCare of Nebraska, Inc., is a managed healthcare provider committed to

Genprex to Present at the Alliance for Regenerative Medicine’s Virtual Cell and Gene Meeting on the Mesa

Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX), a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes, today announced that it will be presenting at the Alliance for Regenerative Medicine’s (ARM) virtual Cell and Gene Meeting on the Mesa, taking place October 12-16, 2020. Michael Redman, Executive Vice President and Chief Operating Officer of Genprex, will lead the company’s presentation.

The 2020 Cell and Gene Meeting on the Mesa will be delivered in a virtual format over the course of five days where attendees will be able to watch company presentations on-demand, in addition to two live-streaming panels each day. The Cell and Gene Meeting on the Mesa is the sector’s foremost annual conference, bringing together senior executives and top decision-makers in the industry to advance cutting-edge research into cures. Tackling the commercialization hurdles facing the cell and gene therapy sector today, this meeting covers a wide range of topics from clinical trial design to alternative payment models to scale-up and supply chain platforms for advanced therapies.

For more information on the conference, or to register, please visit https://www.meetingonthemesa.com.

About Genprex, Inc.

Genprex, Inc. is a clinical-stage gene therapy company developing potentially life-changing technologies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new treatment options for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. The Company’s lead product candidate, GPX-001 (quaratusugene ozeplasmid), is being evaluated as a treatment for non-small cell lung cancer (NSCLC). GPX-001 has a multimodal mechanism of action that has been shown to interrupt cell signaling pathways that cause replication and proliferation of cancer cells; re-establish pathways for apoptosis, or programmed cell death, in cancer cells; and modulate the immune response against cancer cells. GPX-001 has also been shown to block mechanisms that create drug resistance. In January 2020, the U.S. Food and Drug Administration granted Fast Track Designation for GPX-001 for NSCLC in combination therapy with osimertinib (AstraZeneca’s Tagrisso®) for patients with EFGR mutations whose tumors progressed after treatment with osimertinib alone. For more information, please visit the Company’s web site at www.genprex.com or follow Genprex on Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effect of Genprex’s product candidates, alone and in combination with other therapies, on cancer and diabetes, regarding potential, current and planned clinical trials, regarding the Company’s future growth and financial status and regarding our commercial partnerships and intellectual property licenses. Risks that contribute